Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Gilead price target raised to $120 from $105 at Bernstein
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
PharmiWeb23h
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Hosted on MSN1d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
US aid freeze fuels fears of renewed AIDS epidemic: 'People are going to die'
NEWS ANALYSIS. Despite the waiver granted by the US, the global system for fighting HIV – which still causes 630,000 deaths a ...
Assembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trial
Assembly Bio said that it plans to advance ABI-1179 directly into the Phase 1b portion of the study, which will include ...
lifesciencesipreview1d
Gilead deal staves off generic HIV drugs for another six years
Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments.
Pharmabiz2d
US FDA accepts Gilead’s NDA for twice-yearly lenacapavir for HIV prevention under priority review
Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...
Drug therapy lenacapavir may effectively control HIV in Uganda
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...